Fullcircle Wealth LLC Purchases 6,292 Shares of Novo Nordisk A/S (NYSE:NVO)

Fullcircle Wealth LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 31.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,038 shares of the company's stock after purchasing an additional 6,292 shares during the quarter. Fullcircle Wealth LLC's holdings in Novo Nordisk A/S were worth $1,808,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. M. Kulyk & Associates LLC boosted its holdings in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock valued at $274,000 after acquiring an additional 119 shares during the period. Dorsey & Whitney Trust CO LLC boosted its holdings in shares of Novo Nordisk A/S by 0.4% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 31,494 shares of the company's stock valued at $2,709,000 after acquiring an additional 136 shares during the period. BIP Wealth LLC boosted its holdings in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. BIP Wealth LLC now owns 3,642 shares of the company's stock valued at $313,000 after acquiring an additional 138 shares during the period. Xponance Inc. boosted its holdings in shares of Novo Nordisk A/S by 4.9% during the fourth quarter. Xponance Inc. now owns 3,156 shares of the company's stock valued at $271,000 after acquiring an additional 146 shares during the period. Finally, Mystic Asset Management Inc. boosted its holdings in shares of Novo Nordisk A/S by 1.2% during the fourth quarter. Mystic Asset Management Inc. now owns 13,185 shares of the company's stock valued at $1,134,000 after acquiring an additional 150 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on NVO shares. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Stock Up 0.2%

Shares of NYSE NVO traded up $0.14 during mid-day trading on Monday, reaching $69.31. The company had a trading volume of 7,307,060 shares, compared to its average volume of 7,260,984. The stock has a fifty day moving average of $69.96 and a two-hundred day moving average of $75.52. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The company has a market capitalization of $309.47 billion, a price-to-earnings ratio of 20.51, a PEG ratio of 1.35 and a beta of 0.64. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $143.69.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.